Vical Inc.'s stock-bashing Phase III failure against metastatic melanoma with Allovectin (velimogene aliplasmid) caused at least one analyst to question the plasmid DNA platform that is the subject of another late-stage program with Astellas Pharma Inc. in a separate indication, as well as independent efforts.